In an attempt to develop predictive biomarkers of platinum response to primary chemotherapy, Tumiatti et al. [102] developed an HR score based on ex vivo scores of RAD51-possitive cells among the G2 cell fraction after IR damage and reportedly predicted chemotherapy response with high confidence in primary ovarian cancer and ascites. The gene discussed is RAD51; the disease is ovarian carcinoma.